Pharmacotherapy in patients with vasomotor disorders

[1]  M. Beijk,et al.  Presence of Coronary Endothelial Dysfunction, Coronary Vasospasm, and Adenosine-Mediated Vasodilatory Disorders in Patients With Ischemia and Nonobstructive Coronary Arteries , 2022, Circulation. Cardiovascular interventions.

[2]  P. Damman,et al.  Acetylcholine Rechallenge: A First Step Toward Tailored Treatment in Patients With Coronary Artery Spasm. , 2022, JACC. Cardiovascular interventions.

[3]  M. Beijk,et al.  Principles and pitfalls in coronary vasomotor function testing. , 2021, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  J. Stasch,et al.  Soluble guanylate cyclase stimulators and their potential use: a patent review , 2021, Expert opinion on therapeutic patents.

[5]  Jingjing Shi,et al.  The effect of nicorandil in patients with cardiac syndrome X , 2020, Medicine.

[6]  P. Damman,et al.  Ischaemia with no obstructive coronary arteries , 2020, Netherlands Heart Journal.

[7]  M. J. Hashim,et al.  Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study , 2020, Cureus.

[8]  H. Rahman,et al.  Physiological Stratification of Patients With Angina Due to Coronary Microvascular Dysfunction , 2020, Journal of the American College of Cardiology.

[9]  J. Knuuti.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC) , 2020, Russian Journal of Cardiology.

[10]  S. Han,et al.  Clinical impact of statin therapy on vasospastic angina: data from a Korea nation-wide cohort study , 2020, Heart and Vessels.

[11]  Marco Valgimigli,et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. , 2019, European heart journal.

[12]  Christopher J. Rush,et al.  Ischemia and No Obstructive Coronary Artery Disease , 2019, Circulation. Cardiovascular interventions.

[13]  J. Suh,et al.  Clopidogrel plus Aspirin Use is Associated with Worse Long-Term Outcomes, but Aspirin Use Alone is Safe in Patients with Vasospastic Angina: Results from the VA-Korea Registry, A Prospective Multi-Center Cohort , 2019, Scientific Reports.

[14]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[15]  E. Guallar,et al.  Association of statin therapy with clinical outcomes in patients with vasospastic angina: Data from Korean health insurance review and assessment service , 2019, PloS one.

[16]  Christopher J. Rush,et al.  Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. , 2018, Journal of the American College of Cardiology.

[17]  C. Berry,et al.  Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need , 2017, Heart.

[18]  T. Park,et al.  Impact of statin therapy on long-term clinical outcomes of vasospastic angina without significant stenosis: A propensity-score matched analysis. , 2016, International journal of cardiology.

[19]  Jae Joong Lee,et al.  Impact of Renin‐Angiotensin System Inhibitors on Long‐Term Clinical Outcomes of Patients With Coronary Artery Spasm , 2016, Journal of the American Heart Association.

[20]  J. Kaski,et al.  Vasodilator Therapy: Nitrates and Nicorandil , 2016, Cardiovascular Drugs and Therapy.

[21]  K. Sakamoto,et al.  Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm , 2016, Journal of the American Heart Association.

[22]  J. Suh,et al.  The 24-Month Prognosis of Patients With Positive or Intermediate Results in the Intracoronary Ergonovine Provocation Test. , 2015, JACC. Cardiovascular interventions.

[23]  Ryotaro Yamada,et al.  Invasive Evaluation of Patients With Angina in the Absence of Obstructive Coronary Artery Disease , 2015, Circulation.

[24]  Filippo Crea,et al.  Poor Tolerance and Limited Effects of Isosorbide-5-Mononitrate in Microvascular Angina , 2015, Cardiology.

[25]  A. Gallino,et al.  Ranolazine: Drug overview and possible role in primary microvascular angina management. , 2015, International journal of cardiology.

[26]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[27]  V. Figueredo,et al.  Update on ranolazine in the management of angina , 2014, Vascular health and risk management.

[28]  Y. Jeong,et al.  A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina , 2014, Heart.

[29]  F. Crea,et al.  Coronary microvascular dysfunction: an update. , 2014, European heart journal.

[30]  S. Solomon,et al.  The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction , 2013, Journal of the American Heart Association.

[31]  Min Chul Kim,et al.  Clinical outcomes of low-dose aspirin administration in patients with variant angina pectoris. , 2013, International journal of cardiology.

[32]  F. Crea,et al.  Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. , 2013, The American journal of cardiology.

[33]  N. Skolnik,et al.  Management of Hyperglycemia in Type 2 Diabetes , 2012 .

[34]  A. Zito,et al.  HCN Channels and Heart Rate , 2012, Molecules.

[35]  F. Crea,et al.  Mechanisms of Coronary Artery Spasm , 2011, Circulation.

[36]  K. Smith,et al.  In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia , 2011, American heart journal.

[37]  P. Lamendola,et al.  [Coronary microvascular dysfunction. An update]. , 2011, Recenti progressi in medicina.

[38]  P. Vardas,et al.  Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. , 2011, Atherosclerosis.

[39]  K. Smith,et al.  An intravascular ultrasound analysis in women experiencing chest pain in the absence of obstructive coronary artery disease: a substudy from the National Heart, Lung and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). , 2010, Journal of interventional cardiology.

[40]  H. Shimokawa,et al.  Prognostic effects of calcium channel blockers in patients with vasospastic angina--a meta-analysis. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[41]  B. Prendergast,et al.  Low diagnostic yield of elective coronary angiography. , 2010, The New England journal of medicine.

[42]  S. Kelsey,et al.  A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). , 2010, American heart journal.

[43]  U. Krishnan,et al.  First Report of the Successful Use of Bosentan in Refractory Vasospastic Angina , 2010, Cardiology.

[44]  Pamela S Douglas,et al.  Low diagnostic yield of elective coronary angiography. , 2010, The New England journal of medicine.

[45]  P. Kamphuisen,et al.  Improved myocardial perfusion preceding clinical response on bosentan treatment for coronary vasospasm , 2009, Acta cardiologica.

[46]  B. Mayer,et al.  The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles , 2008, British journal of pharmacology.

[47]  A. Hirayama,et al.  Treatment of Coronary Spastic Angina With a Statin in Addition to a Calcium Channel Blocker: A Pilot Study , 2008, Journal of cardiovascular pharmacology.

[48]  M. Horie,et al.  Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. , 2008, Journal of the American College of Cardiology.

[49]  H. Kishida,et al.  Administration of the Rho-kinase inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina , 2008, Coronary artery disease.

[50]  R. Mortensen,et al.  Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature , 2008, Circulation research.

[51]  H. Yasue,et al.  Coronary artery spasm--clinical features, diagnosis, pathogenesis, and treatment. , 2008, Journal of cardiology.

[52]  S. Nekolla,et al.  Effect of the Angiotensin Receptor Blocker Valsartan on Coronary Microvascular Flow Reserve in Moderately Hypertensive Patients with Stable Coronary Artery Disease , 2007, Microcirculation.

[53]  J. Pernow,et al.  The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. , 2007, Cardiovascular research.

[54]  Pimonrat Ketsawatsomkron,et al.  Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. , 2007, American journal of physiology. Heart and circulatory physiology.

[55]  B. Yan,et al.  The mystery of coronary artery spasm. , 2007, Heart, lung & circulation.

[56]  A. Herman,et al.  Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina. , 2005, Atherosclerosis.

[57]  L. Lemberg,et al.  Prinzmetal's angina. , 2004, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[58]  C. Pizzi,et al.  Angiotensin-Converting Enzyme Inhibitors and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase in Cardiac Syndrome X: Role of Superoxide Dismutase Activity , 2004, Circulation.

[59]  M. Sekiya,et al.  Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. , 2003, The American journal of cardiology.

[60]  R. Nair,et al.  Alteration of myocardial mechanics in marginal magnesium deficiency. , 2002, Magnesium research.

[61]  E. Schiffrin,et al.  PPARα Activator Effects on Ang II–Induced Vascular Oxidative Stress and Inflammation , 2002 .

[62]  Shing‐Jong Lin,et al.  Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. , 2002, The American journal of cardiology.

[63]  D. DiFrancesco,et al.  Current-dependent Block of Rabbit Sino-Atrial Node If Channels by Ivabradine , 2002, The Journal of general physiology.

[64]  A. Takeshita,et al.  Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Patients With Vasospastic Angina , 2002, Circulation.

[65]  P. Libby,et al.  Endothelial function and coronary artery disease , 2001, Current opinion in lipidology.

[66]  A. Takeshita,et al.  Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  V. Dzau.  Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. , 2001, Hypertension.

[68]  T. Cheng.  Ergonovine Maleate and β-Blockers for Prinzmetal’s Angina , 2001 .

[69]  G. Kajiyama,et al.  The preventive effect of magnesium on coronary spasm in patients with vasospastic angina. , 2000, Chest.

[70]  M. Fujishima,et al.  Renin-Angiotensin System Blockade Improves Endothelial Dysfunction in Hypertension , 2000, Hypertension.

[71]  M. Kinoshita,et al.  Effects of intravenous nicorandil on coronary circulation in humans: plasma concentration and action mechanism. , 2000, Journal of cardiovascular pharmacology.

[72]  M. Devynck,et al.  Influence of SIN-1 on Platelet Ca2+ Handling in Patients with Suspected Coronary Artery Disease: Ex Vivo and In Vitro Studies , 2000, Thrombosis and Haemostasis.

[73]  A. Takeshita,et al.  Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. , 2000, Circulation.

[74]  HiroakiShimokawa,et al.  Inhibition of Myosin Phosphatase by Upregulated Rho-Kinase Plays a Key Role for Coronary Artery Spasm in a Porcine Model With Interleukin-1β , 2000 .

[75]  C. Jones,et al.  Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.

[76]  A. Somlyo,et al.  Signal transduction by G‐proteins, Rho‐kinase and protein phosphatase to smooth muscle and non‐muscle myosin II , 2000, The Journal of physiology.

[77]  G. Rosano,et al.  Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance. , 1999, Cardiologia.

[78]  R. Foale,et al.  Effect of α1-Adrenoceptor Blockade on Coronary Vasodilator Reserve in Cardiac Syndrome X , 1999 .

[79]  D. Tousoulis,et al.  Vasomotion of Coronary Arteries: From Nitrates to Nitric Oxide , 1999, Cardiovascular Drugs and Therapy.

[80]  R. Marfella,et al.  Effects of Perindopril and Carvedilol on Endothelium-Dependent Vascular Functions in Patients With Diabetes and Hypertension , 1998, Diabetes Care.

[81]  J. Kaski,et al.  Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. , 1998, European heart journal.

[82]  S. Nalbantgil,et al.  Therapeutic Benefits of Cilazapril in Patients with Syndrome X , 1998, Cardiology.

[83]  R. Zulli,et al.  Effects of long‐term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy , 1997, Journal of hypertension.

[84]  T. Ueda,et al.  Relation between severity of magnesium deficiency and frequency of anginal attacks in men with variant angina. , 1996, Journal of the American College of Cardiology.

[85]  B. Winkelmann,et al.  Clinical Pharmacokinetics of Molsidomine , 1996, Clinical pharmacokinetics.

[86]  B. Strauer,et al.  Improvement of coronary flow reserve after long-term therapy with enalapril. , 1996, Hypertension.

[87]  K. Shirato,et al.  Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. , 1995, Journal of cardiovascular pharmacology.

[88]  M. Fujita,et al.  Comparison of frequency of magnesium deficiency in patients with vasospastic angina and fixed coronary artery disease. , 1995, The American journal of cardiology.

[89]  Å. Wennmalm,et al.  NO‐dependent and ‐independent elevation of plasma levels of insulin and glucose in rats by L‐arginine , 1994, British journal of pharmacology.

[90]  A. Quyyumi,et al.  Imipramine in patients with chest pain despite normal coronary angiograms. , 1994, The New England journal of medicine.

[91]  P. Marraccini,et al.  Adrenergically mediated coronary vasoconstriction in patients with Syndrome X , 1994, Cardiovascular Drugs and Therapy.

[92]  B. Hellwig.  Signal transduction by G proteins , 1994, Medizinische Monatsschrift fur Pharmazeuten.

[93]  T. Giles,et al.  Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. , 1993, Journal of the American College of Cardiology.

[94]  T. Fischell,et al.  Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. , 1993, Journal of the American College of Cardiology.

[95]  M. Murayama,et al.  Magnesium content of erythrocytes in patients with vasospastic angina , 1991, Cardiovascular Drugs and Therapy.

[96]  M. Yanagisawa,et al.  Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris. , 1991, Circulation.

[97]  G. Rubanyi,et al.  Endothelins , 1991, The Lancet.

[98]  K. Kugiyama,et al.  Magnesium deficiency detected by intravenous loading test in variant angina pectoris. , 1990, The American journal of cardiology.

[99]  M. Emdin,et al.  Improved exercise capacity with acute aminophylline administration in patients with syndrome X. , 1989, Journal of the American College of Cardiology.

[100]  N. Taira,et al.  Nicorandil as a hybrid between nitrates and potassium channel activators. , 1989, The American journal of cardiology.

[101]  J. Hodgson,et al.  Direct vasoconstriction and endothelium-dependent vasodilation. Mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries. , 1989, Circulation.

[102]  E. Picano,et al.  Aminophylline termination of dipyridamole stress as a trigger of coronary vasospasm in variant angina. , 1988, The American journal of cardiology.

[103]  J. Conti,et al.  Isosorbide dinitrate and nifedipine in variant angina pectoris. , 1985, American heart journal.

[104]  M. Winniford,et al.  Alpha–adrenergic Blockade for Variant Angina: A Long–term, Double–blind, Randomized Trial , 1983, Circulation.

[105]  B. Weksler,et al.  Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. , 1983, The New England journal of medicine.

[106]  A. Keren,et al.  Prazosin therapy for refractory variant angina. , 1983, American heart journal.

[107]  C. Kawai,et al.  Effect of aspirin in large doses on attacks of variant angina. , 1983, American heart journal.

[108]  M. Rubenfire,et al.  Randomized withdrawal from nifedipine: placebo-controlled study in patients with coronary artery spasm. , 1982, American heart journal.

[109]  L. Hillis,et al.  A controlled trial of verapamil for Prinzmetal's variant angina. , 1981, The New England journal of medicine.

[110]  E. Antman,et al.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. , 1980, The New England journal of medicine.

[111]  R. Battye,et al.  A Retrospective Evaluation of Nifedipine Therapy in Prinzmetal's Angina , 1979, The Journal of international medical research.

[112]  W. C. Sheldon,et al.  Ergonovine maleate provocative test for coronary arterial spasm. , 1978, The American journal of cardiology.

[113]  H. Yasue,et al.  Pathogenesis and treatment of angina pectoris at rest as seen from its response to various drugs. , 1978, Japanese circulation journal.

[114]  J. Muller,et al.  Nifedipine Therapy for Prinzmetal's Angina , 1978, Circulation.

[115]  M. Freeman,et al.  α-Adrenoceptor-Mediated Coronary Artery Spasm , 1976 .

[116]  Hiroaki Shimokawa,et al.  International standardization of diagnostic criteria for microvascular angina. , 2018, International journal of cardiology.

[117]  M. Taskinen,et al.  ESC/EAS Guidelines for the Management of Dyslipidaemias , 2013 .

[118]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[119]  W. Frishman.  Calcium Channel Blockers: Differences Between Subclasses , 2007, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[120]  Pimonrat Ketsawatsomkron,et al.  Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK 2 activation , 2007 .

[121]  Ayman A El Menyar.  Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. , 2006, Journal of postgraduate medicine.

[122]  A. E. Menyar.  Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. , 2006 .

[123]  Hiroaki Shimokawa,et al.  Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. , 2003, Journal of the American College of Cardiology.

[124]  E. Schiffrin,et al.  Vascular biology of endothelin. , 1998, Journal of cardiovascular pharmacology.

[125]  L. Opie.  Calcium channel antagonists in the management of anginal syndromes: changing concepts in relation to the role of coronary vasospasm. , 1996, Progress in cardiovascular diseases.